New combo therapy targets Hard-to-Treat cancers
NCT ID NCT07387081
First seen Feb 04, 2026 · Last updated May 19, 2026 · Updated 13 times
Summary
This study tests a new drug called LM-24C5 combined with other cancer treatments for people with advanced solid tumors that have a specific protein (CEACAM5). The goal is to see if the combination shrinks tumors and is safe. About 130 adults aged 18-80 whose cancer has returned or not responded to standard therapy will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fujian Cancer Hospital
RECRUITINGFuzhou, Fujian, 350014, China
Contact
-
Shanghai East Hospital
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, 200123, China
Contact
Conditions
Explore the condition pages connected to this study.